Bosakitug vs SKB575

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: TSLP · full Atopic Dermatitis pipeline

Bosakitug

Developed by Aclaris Therapeutics under a licence from Biosion

Phase 2 in Atopic Dermatitismonoclonal antibody
Weak signal

NCT05932654 · Phase 2 · completed

The study treated 22 participants in one open-label, non-randomized arm without a placebo or active comparator. Its clinical primary efficacy endpoint was reported for 17 participants, but there was no controlled comparison or formal primary endpoint test, so the favorable response rate provides limited evidence of efficacy.

Reported efficacy

Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26; Safety Profile of Study Treatment (Day 1 to Week 36): Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 (Week 26): 300 mg 94.1% (95% CI 71.3 to 99.9) (not_applicable)

Result source: NCT05932654

SKB575

Developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners

Phase 1 in Atopic Dermatitisbispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07488065 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBosakitugSKB575
EASI-75—Not reported—Not reported
IGA 0/1 with 2-point improvement—Not reported—Not reported
EASI-90—Not reported—Not reported
EASI, % change—Not reported—Not reported

EASI-75

Bosakitug
—Not reported
SKB575
—Not reported

IGA 0/1 with 2-point improvement

Bosakitug
—Not reported
SKB575
—Not reported

EASI-90

Bosakitug
—Not reported
SKB575
—Not reported

EASI, % change

Bosakitug
—Not reported
SKB575
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SKB575: no structured comparison results are available for Atopic Dermatitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bosakitug: 3 of 4 rows · SKB575: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBosakitug
Dropout rate
22.7%300 mg
NCT05932654 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2
Discontinued due to AEs
—300 mg
NCT05932654 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2
Serious AEs
0%300 mg
NCT05932654 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2
Most frequent reported AEs
300 mg
headache 22.7%
NCT05932654 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bosakitug

EASI-75 94.1% (n=17) @ 26wk300 mg
responder rate · % of participants
No placebo or comparator arm
NCT05932654 · Phase 2 · monotherapy · Atopic Dermatitis · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bosakitug's landscape · SKB575's landscape